Terns Pharmaceuticals (TERN)
(Delayed Data from NSDQ)
$5.67 USD
-0.41 (-6.74%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $5.67 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Terns Pharmaceuticals, Inc.'s return on equity, or ROE, is -26.56% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.08%. While this shows that TERN has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
TERN 5.67 -0.41(-6.74%)
Will TERN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TERN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TERN
Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround
Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN)
TERN: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug
Other News for TERN
Terns Pharma (TERN) Projects Financial Stability Until 2028 with Ongoing Trials
Terns Pharmaceuticals GAAP EPS of -$0.26 beats by $0.03
Terns Pharmaceuticals reports Q2 EPS (26c), consensus (29c)
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule ...
Commit To Buy Terns Pharmaceuticals At $3, Earn 23.3% Using Options